Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 2079-2086, 2006. First published September 21, 2006; 10.1373/clinchem.2006.072496
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.072496v1
52/11/2079    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zoeger, A.
Right arrow Articles by Dahlmann, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zoeger, A.
Right arrow Articles by Dahlmann, B.
Related Collections
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2006;52:2079-2086.)
© 2006 American Association for Clinical Chemistry, Inc.

General Clinical Chemistry

Circulating Proteasomes Are Functional and Have a Subtype Pattern Distinct from 20S Proteasomes in Major Blood Cells

Annette Zoeger1, Michael Blau1, Karl Egerer2, Eugen Feist2 and Burkhardt Dahlmann1,a

1 Institut für Biochemie, Charité-Universitätsmedizin-Berlin, Berlin, Germany.
2 Klinik für Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin-Berlin, Berlin, Germany.

aAddress correspondence to this author at: Charité-Universitätsmedizin-Berlin; Institut für Biochemie; Monbijoustr. 2, 10117 Berlin, Germany. Fax 49-30-450528916; e-mail burkhardt.dahlmann{at}charite.de.

Background: 20S proteasomes, the proteolytic core particles of the major intracellular protein degradative pathway, are potential disease markers because they are detectable in human plasma as circulating proteasomes and their concentrations are increased in patients suffering from various diseases. To investigate the origin of circulating proteasomes, we compared some of their features with those of proteasomes isolated from major blood cells.

Methods: We isolated circulating proteasomes from the plasma of 2 patients with rheumatoid arthritis and 2 with systemic lupus erythematosus and from human plasma from healthy donors. We purified the proteasomes to apparent homogeneity and then used electron microscopy for imaging and chromatography for subtype spectrum analysis. We compared subtype results with those from 20S proteasomes purified from 4 major blood cell populations. We also tested proteasomes for enzymatic activity and immunosubunit content.

Results: Circulating proteasomes from plasma of healthy donors and from patients with autoimmune disease were found to have the same size and shape as erythrocyte proteasomes, be proteolytically active, and contain standard- and immunosubunits. Chromatography revealed 6 circulating proteasome subtype peaks in healthy donor plasma and 7 in patient donor plasma. Proteasomes from erythrocytes had 3 subtype peaks and those of monocytes, T-lymphocytes, and thrombocytes each had 5 different subtype peaks.

Conclusion: Circulating proteasomes were intact and enzymatically active in plasma from healthy donors and from patients with autoimmune disease. Because the subtype patterns of circulating proteasomes clearly differ from those of proteasomes from blood cells, these cells cannot be regarded as a major source of circulating proteasomes.




The following articles in journals at HighWire Press have cited this article:


Home page
 Cardiovasc ResHome page
A. Kloss, S. Meiners, A. Ludwig, and B. Dahlmann
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors
Cardiovasc Res, July 31, 2009; (2009) cvp217v2.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
F. H. Jansen, J. Krijgsveld, A. van Rijswijk, G.-J. van den Bemd, M. S. van den Berg, W. M. van Weerden, R. Willemsen, L. J. Dekker, T. M. Luider, and G. Jenster
Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins
Mol. Cell. Proteomics, June 1, 2009; 8(6): 1192 - 1205.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. Majetschak, M. Perez, L. T. Sorell, J. Lam, M. E. Maldonado, and R. W. Hoffman
Circulating 20S Proteasome Levels in Patients with Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Clin. Vaccine Immunol., September 1, 2008; 15(9): 1489 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Scheffler, U. Kuckelkorn, K. Egerer, T. Dorner, K. Reiter, A. Soza, G.-R. Burmester, and E. Feist
Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 ({beta}1i), MECL1 ({beta}2i) and LMP7 ({beta}5i)
Rheumatology, May 1, 2008; 47(5): 622 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Szerafin, K. Hoetzenecker, S. Hacker, A. Horvath, A. Pollreisz, P. Arpad, A. Mangold, T. Wliszczak, M. Dworschak, R. Seitelberger, et al.
Heat Shock Proteins 27, 60, 70, 90{alpha}, and 20S Proteasome in On-Pump Versus Off-Pump Coronary Artery Bypass Graft Patients
Ann. Thorac. Surg., January 1, 2008; 85(1): 80 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. U. Sixt, M. Beiderlinden, H. P. Jennissen, and J. Peters
Extracellular proteasome in the human alveolar space: a new housekeeping enzyme?
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1280 - L1288.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.